N06AA12 doxepin
NERVOUS SYSTEM ›PSYCHOANALEPTICS ›ANTIDEPRESSANTS ›Non-selective monoamine reuptake inhibitors
健保收載品項 TFDA 在效許可證 5 FDA 已核准
台灣藥品與外觀
健保收載品名："強生" 可立安 膠囊 25 毫克、''十全''杜使平膠囊２５毫克（杜西平）、凱舒錠２５公絲、悅得靜膜衣錠 10 毫克、神寧健膠囊１０公絲、神寧健膠囊１０毫克、神寧健膠囊２５公絲、神寧健膠囊２５毫克
無外觀照
鹽酸多士平
資料來源：食藥署「西藥許可證」＋「藥品 ATC 碼」＋「藥品外觀」＋「藥品仿單或外盒」開放資料。外觀照與仿單連結指向食藥署原始檔。
適應症
台灣 TFDA 核准適應症
- 焦慮狀態、憂鬱病。
- 抗憂鬱症。
美國 FDA 適應症（英文原文對照）
INDICATIONS AND USAGE Doxepin Hydrochloride Capsules, USP are recommended for the treatment of: 1. Psychoneurotic patients with depression and/or anxiety. 2. Depression and/or anxiety associated with alcoholism (not to be taken concomitantly with alcohol). 3. Depression and/or anxiety associated with organic disease (the possibility of drug interaction should be considered if the patient is receiving other drugs concomitantly). 4. Psychotic depressive disorders with associated anxiety including involutional depression and manic-depressive disorders. The target symptoms of psychoneurosis that respond particularly well to doxepin hydrochloride capsules include anxiety, tension, depression, somatic symptoms and concerns, sleep disturbances, guilt, lack of energy, fear, apprehension and worry. Clinical experience has shown that doxepin hydrochloride capsules are safe and well tolerated even in the elderly patient. Owing to lack of clinical experience in the pediatric population, doxepin hydrochloride capsules are not recommended for use in children under 12 years of age.
資料來源：食藥署西藥許可證適應症（中文）、openFDA US SPL（英文，僅供對照）。
健保給付規定
查無健保特殊給付規定條款；本藥品依一般健保藥品支付規定給付。
實證補充
本藥品尚無實證補充整理（未來新增 Review／指引知識時補列）。
台灣藥品與適應症：食藥署西藥許可證＋ATC＋外觀＋仿單開放資料 · FDA：openFDA US SPL · 健保給付：健保署「全民健康保險藥品給付規定」（更新日 2026-06-09）· 實證補充：人工彙整。 本頁為資訊整理，實際給付與適應症以主管機關公告為準。